Polaryx Therapeutics (NASDAQ:PLYX) Earns Strong-Buy Rating from Analysts at Raymond James Financial

Stock analysts at Raymond James Financial initiated coverage on shares of Polaryx Therapeutics (NASDAQ:PLYX) in a research note issued to investors on Thursday,Benzinga reports. The firm set a “strong-buy” rating and a $6.00 price target on the stock. Raymond James Financial’s price target indicates a potential upside of 169.06% from the company’s previous close.

A number of other research firms have also weighed in on PLYX. Wall Street Zen lowered Polaryx Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 12th. HC Wainwright started coverage on shares of Polaryx Therapeutics in a report on Thursday, July 9th. They issued a “buy” rating and a $7.00 price objective for the company. Zacks Research upgraded shares of Polaryx Therapeutics to a “hold” rating in a research report on Friday, July 10th. Finally, Weiss Ratings upgraded Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.67.

Polaryx Therapeutics Stock Up 1.4%

PLYX opened at $2.23 on Thursday. The firm has a market capitalization of $111.16 million and a price-to-earnings ratio of -44.60. Polaryx Therapeutics has a twelve month low of $1.86 and a twelve month high of $48.91. The stock’s 50-day simple moving average is $2.33.

Polaryx Therapeutics (NASDAQ:PLYX) last released its earnings results on Monday, March 23rd. The company reported ($0.03) earnings per share for the quarter. Equities analysts anticipate that Polaryx Therapeutics will post -0.22 EPS for the current year.

Insider Transactions at Polaryx Therapeutics

In related news, CEO Alex Keun Mo Yang bought 88,453 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was purchased at an average cost of $4.07 per share, with a total value of $360,003.71. Following the purchase, the chief executive officer directly owned 24,233,249 shares of the company’s stock, valued at $98,629,323.43. This trade represents a 0.37% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 45.82% of the company’s stock.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.